With the upcoming top-tier oncology conference, more than 250 domestically innovative drugs are poised for release, with ADC drugs potentially taking center stage.

①The 117th Annual Meeting of the American Association for Cancer Research (AACR) will be held in San Diego from April 17 to 22; ②This year, 104 Chinese pharmaceutical companies will present at AACR, among which research findings on 92 ADC drugs are expected to be showcased; ③Guohai Securities noted that ADC drugs already on the market are experiencing rapid growth, and many optimized products from domestic enterprises show potential to be best-in-class.

cls.cnApr 1 11:28

At a Glance: March's Hottest IPOs - Shangmi Technology Approved! Four New Stocks, Including ZhaoWei Electromechanical and EastControl, Undergoing Enthusiastic Subscription.

Hello, fellow investors! The New Stock Observer is here to provide updates on the popular HK IPOs in March and throughout 2026. Fellow investors, check it out now!

Futu NewsFeb 28 09:55

Changchun High-Tech Industry's Unit Gets Nod for GenSci141 Ointment Clinical Trial

MT NewswiresFeb 25 12:37

Sinovac Pharmaceuticals Aims for Dual A+H Listing, Valued at 6.2 Billion USD, Yet Innovation Potential May Be Limited

In the past two years, the trend of "A+H" listings has surged again. To date, more than 100 A-share companies are at various stages of going public in Hong Kong. (Refer to the list of A+H dual-listed companies at the end of this article.) Among these, there are no shortage of biopharmaceutical firms; Hengrui Pharma has already successfully listed on the Hong Kong stock exchange, while Baili Tianhe remains stuck at the final stage of its listing process. Additionally, Sinovac Biotech, Maiwei Bio, Changchun High-Tech, Beta Pharma, Yuekang Pharma, Zelgen Biopharma, SinoPharm Nova, Yifang Bio, Oulin Bio, and Bai Bioscience have all submitted their applications to the Hong Kong Stock Exchange. According to Gelonghui, Sinovac Biotech Co., Ltd. (referred to as: Sinovac Pharma) has submitted its application to the Hong Kong Stock Exchange.

Gelonghui FinanceFeb 11 17:58

Changchun High-Tech Gets Nod for GenSci136 Clinical Trial As IgAN Treatment

MT NewswiresFeb 10 12:21

Chinese Drug Regulator Accepts Changchun High-Tech Unit's Clinical Trial Application for GenSci136 Injection

MT NewswiresFeb 4 12:46